Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China
Lorlatinib demonstrates strong efficacy and manageable safety, especially in first-line treatment of advanced ALK-positive NSCLC, supporting its role as an effective treatment option.
Authors
- Guangming Tian
- Xiaoling Chen (ORCID: https://orcid.org/0000-0002-2271-1140)
- Ziran Zhang (ORCID: https://orcid.org/0000-0001-7003-2735)
- Jindi Han
- Di Wu (ORCID: https://orcid.org/0000-0002-6064-9990)
- Jie Zhang
- Xinliang Zhao
- Jun Nie
- Sen Han (ORCID: https://orcid.org/0000-0002-5891-5225)
- Xiangjuan Ma (ORCID: https://orcid.org/0000-0002-1118-3725)
- Ling Dai (ORCID: https://orcid.org/0009-0005-5386-9089)
- Jian Fang
- Jieran Long
- Weiheng Hu
Institutions
- Peking University (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fonc.2025.1577607
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Wu Jieping Medical Foundation